Switzerland-based Helsinn Group hopes to market its first targeted cancer therapy in the US though a newly agreed global collaboration and licensing pact with BridgeBio Pharma, Inc. to jointly develop and commercialize the latter’s FGFR1-3 inhibitor, infigratinib.
Helsinn And BridgeBio Ink Infigratinib Cancer Pact
Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology
Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.
